10% OFF SITEWIDE

00h00m00s
use codeAUGUST10stacks on top of bundle savings
side-by-side research comparison

CJC-1295 / Ipamorelin vs GLP-3 RTA

CJC-1295 / Ipamorelin and GLP-3 RTA come from different research areas and are studied in largely separate models — researchers usually compare them when scoping a broader protocol.

✓ both US-made · third-party tested · batch COA on every order

at a glance

CJC-1295 / IpamorelinGLP-3 RTA
compound classCo-formulated GHRH-analog and secretagogue blendSynthetic triple-agonist peptide
research arealongevity & cellularweight & metabolic
purity standard99%+ by HPLC99%+ by HPLC
manufacturedUnited StatesUnited States
batch COApublished per lotpublished per lot
price from$169.49$155.99
availabilityin stockin stock

what each one is

CJC-1295 / Ipamorelin

Co-formulated GHRH-analog and secretagogue blend

CJC-1295 / Ipamorelin is a co-formulated research blend of two peptides that act at separate receptors. CJC-1295 without DAC, also referred to as Mod GRF 1-29, is a modified 29-amino-acid analog of growth-hormone-releasing hormone characterized as a GHRH-receptor agonist. Ipamorelin is a synthetic pentapeptide characterized as a selective agonist at the growth-hormone secretagogue receptor, GHS-R1a.

full CJC-1295 / Ipamorelin profile →

GLP-3 RTA

Synthetic triple-agonist peptide

GLP-3 RTA is a synthetic single-chain peptide engineered to act at three related class B G-protein-coupled receptors at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Its backbone is derived from the incretin peptide family and carries a fatty-acid modification that extends plasma half-life in pre-clinical systems, making it a widely cited reference agonist in incretin-receptor research.

full GLP-3 RTA profile →

where the research differs

Both compounds are supplied strictly for laboratory research use only. Reported research contexts for each:

CJC-1295 / Ipamorelin

  • Dual-pathway GHRH-receptor and GHS-R1a signaling research
  • Receptor cross-talk and signal-transduction research models
  • Comparative agonist research versus single-component preparations
  • Endocrine-signaling research in cellular and pre-clinical models
  • Peptide stability and analog structure–activity research

GLP-3 RTA

  • GLP-1, GIP, and glucagon receptor agonism research
  • cAMP and class B GPCR signaling research models
  • Comparative single-, dual-, and triple-agonist pharmacology studies
  • Metabolic-pathway and nutrient-handling research models
  • Peptide half-life, lipidation, and stability research

shop either compound

Any 2 different compounds take 20% off, any 3 take 30% — applied automatically in the cart, no code. Orders placed Monday–Friday ship by 2pm CT, free over $100.

build a stack with both →

frequently asked

What is CJC-1295 / Ipamorelin?

It is a co-formulated research blend of CJC-1295 without DAC (also called Mod GRF 1-29), a GHRH analog, and ipamorelin, a selective GHS-R1a agonist. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.

What is the difference between CJC-1295 with and without DAC?

The DAC (drug affinity complex) modification is a chemical addition studied for its effect on the analog's circulating half-life in pre-clinical models. The no-DAC form, Mod GRF 1-29, lacks that modification and is the component used in this blend.

What is GLP-3 RTA?

GLP-3 RTA is a synthetic peptide that acts as an agonist at three receptors — GLP-1, GIP, and glucagon. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.

What is GLP-3 RTA studied for in research?

In in-vitro and pre-clinical models it is used as a reference agonist in incretin-receptor pharmacology, cAMP signaling, and metabolic-pathway research. Verve makes no claims about use in humans or animals.

related comparisons

verve products are sold for laboratory research and development purposes only and are not intended for human or veterinary use of any kind. statements on this site have not been evaluated by the FDA.